IL17A and psoriasis: IL-17A inhibition was shown to exhibit a faster mode of onset compared to IL-23 inhibition (15), which is in line with the idea that blocking a “downstream” effector cytokine such as IL-17A should reduce psoriasis symptoms faster than blocking an “upstream” regulatory cytokine such as IL-23.